Deciphera Pharmaceuticals to Present at 27th Annual Oppenheimer Healthcare Conference

WALTHAM, Mass.–(BUSINESS WIRE)– Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company
focused on addressing key mechanisms of tumor drug resistance, today
announced that Michael D. Taylor, Ph.D., Deciphera’s President and Chief
Executive Officer will present a corporate update at the upcoming 27th
Annual Oppenheimer Healthcare Conference at The Westin New York Grand
Central in New York City on Tuesday, March 21, 2017 at 2:45 p.m. ET in
Track 3.

About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is
a clinical-stage biopharmaceutical company focused on improving the
lives of cancer patients by tackling key mechanisms of drug resistance
that limit the rate and/or durability of response to existing cancer
therapies. Our small molecule drug candidates are directed against an
important family of enzymes called kinases, known to be directly
involved in the growth and spread of many cancers. We use our deep
understanding of kinase biology together with a proprietary chemistry
library to purposefully design compounds that maintain kinases in a
“switched off’ or inactivated conformation. These therapies comprise
tumor-targeted agents designed to address therapeutic resistance causing
mutations and immuno-targeted agents designed to control the activation
of immunokinases that suppress critical immune system regulators, such
as macrophages. We have used our platform to develop a diverse pipeline
of tumor-targeted and immuno-targeted drug candidates designed to
improve outcomes for patients with cancer by improving the quality, rate
and/or durability of their response to treatment.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170316005261/en/